Clinical trials: Advanced Hepatocellular Carcinoma
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Carcinoma, Hepatocellular
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)
- Trial name
- NCT05653427
- Testing
- Amivantamab
- Where
- 13 sites in China
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Hepatocellular Carcinoma
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of cabozantinib in Japanese participants with advanced hepatocellular carcinoma (HCC) who have received prior systemic anticancer therapy.
- Trial name
- NCT03586973
- Testing
- Cabozantinib
- Where
- 17 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Takeda
Hepatocellular Carcinoma
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC.
- Trial name
- NCT03519997
- Testing
- Pembrolizumab, Bavituximab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- David Hsieh
Hepatocellular Carcinoma
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden.
- Trial name
- NCT05249569
- Testing
- Axitinib, Avelumab, Bavituximab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy…
- Trial name
- NCT04327700
- Testing
- TheraBionic, Regorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
This phase II trial is studying how well giving cediranib maleate together with combination chemotherapy works in treating patients with advanced biliary cancers.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01229111
- Testing
- cediranib maleate, oxaliplatin, leucovorin calcium
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or…
- Conditions
- Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT02159989
- Testing
- Sapanisertib, Ziv-Aflibercept
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
HCC
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically…
- Trial name
- NCT04251117
- Testing
- GNOS-PV02, INO-9012, Pembrolizumab
- Where
- 3 sites in United States, New Zealand
- Volunteers
- 36 people
- Sponsor
- Geneos Therapeutics
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
- Conditions
- Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms
- Trial name
- NCT02834780
- Testing
- H3B-6527
- Where
- 44 sites in United States, Belgium and 9 more
- Volunteers
- 128 people
- Sponsor
- H3 Biomedicine Inc.
Hepatocellular Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02576509
- Testing
- Nivolumab, Sorafenib
- Where
- 138 sites in United States, Australia and 20 more
- Volunteers
- 743 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Hepatocellular
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects…
- Trial name
- NCT01988493
- Testing
- Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 117 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatocellular Carcinoma
Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
This is a single-arm, single-center, open-label trial of pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcinoma as second-line treatment after failure of sorafenib.
- Trial name
- NCT03163992
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body (advanced or metastatic).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04828486
- Testing
- Futibatinib, Pembrolizumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo…
- Trial name
- NCT05359861
- Testing
- Casdozokitug, Atezolizumab, Bevacizumab
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Coherus Oncology, Inc.
Hepatocellular Carcinoma
Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
This study enrolls patients who have relapsed/advanced hepatocellular carcinoma (HCC, BCLC stage C). The HCC tumor relapsed or metastasized through the body after standard treatment or the patients cannot receive standard…
- Trial name
- NCT03175679
- Testing
- iNKT cells, IL-2, Tegafur
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing YouAn Hospital
Hepatocellular Carcinoma Non-Resectable
A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210 in subjects with advanced HCC who failed or intolerable to prior systemic treatment.
- Trial name
- NCT02989922
- Testing
- SHR-1210
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.